Abstract
The selective κ opioid receptor agonist nalfurafine was launched in 2009 as an antipruritic drug for patients undergoing hemodialysis. It is the first clinically used compound with high selectivity for the κ opioid receptor. Nalfurafine had a different pharmacological feature from other κ opioid agonists. Nalfurafine induced neither addictive nor aversive effects, whereas other κ agonists such as U- 50,488H or salvinorin A produced psychotomimetic effects like dysphoria. Therefore, identification of the essential structural moieties of nalfurafine for binding to the κ opioid receptor was important for elucidation of the pharmacological discrepancies observed with these κ opioid agonists. Based on the investigations of various nalfurafine derivatives, the essential structural moieties of nalfurafine were unveiled. Both the nitrogen substituted by a cyclopropylmethyl group and the 6-amide side chain were indispensable. The phenol ring was important for obtaining strong binding affinities for the opioid receptors, but not indispensable for exerting selectivity for the κ receptor. This structure-activity information is expected to lead to the development of novel κ opioid receptor selective agonists.
Keywords: Opioid receptor, κ opioid receptor, agonist, nalfurafine, address part, U-50, 488H, active conformation.
Current Pharmaceutical Design
Title:Essential Structure of the κ Opioid Receptor Agonist Nalfurafine for Binding to the κ Receptor
Volume: 19 Issue: 42
Author(s): Hiroshi Nagase and Hideaki Fujii
Affiliation:
Keywords: Opioid receptor, κ opioid receptor, agonist, nalfurafine, address part, U-50, 488H, active conformation.
Abstract: The selective κ opioid receptor agonist nalfurafine was launched in 2009 as an antipruritic drug for patients undergoing hemodialysis. It is the first clinically used compound with high selectivity for the κ opioid receptor. Nalfurafine had a different pharmacological feature from other κ opioid agonists. Nalfurafine induced neither addictive nor aversive effects, whereas other κ agonists such as U- 50,488H or salvinorin A produced psychotomimetic effects like dysphoria. Therefore, identification of the essential structural moieties of nalfurafine for binding to the κ opioid receptor was important for elucidation of the pharmacological discrepancies observed with these κ opioid agonists. Based on the investigations of various nalfurafine derivatives, the essential structural moieties of nalfurafine were unveiled. Both the nitrogen substituted by a cyclopropylmethyl group and the 6-amide side chain were indispensable. The phenol ring was important for obtaining strong binding affinities for the opioid receptors, but not indispensable for exerting selectivity for the κ receptor. This structure-activity information is expected to lead to the development of novel κ opioid receptor selective agonists.
Export Options
About this article
Cite this article as:
Nagase Hiroshi and Fujii Hideaki, Essential Structure of the κ Opioid Receptor Agonist Nalfurafine for Binding to the κ Receptor, Current Pharmaceutical Design 2013; 19 (42) . https://dx.doi.org/10.2174/138161281942140105165011
DOI https://dx.doi.org/10.2174/138161281942140105165011 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neurodegeneration and the Heat Shock Protein 70 Machinery: Implications for Therapeutic Development
Current Topics in Medicinal Chemistry Reverse Pharmacognosy: Another Way to Harness the Generosity of Nature
Current Pharmaceutical Design Novel Derivatives of Benfluron and Dimefluron Synthesis and Anticancer activity
Letters in Drug Design & Discovery Computational Approaches Towards Kinases as Attractive Targets for Anticancer Drug Discovery and Development
Anti-Cancer Agents in Medicinal Chemistry The Role of Fibroblast Growth Factors in Tumor Growth
Current Cancer Drug Targets Radioiodinated Ginger Compounds (6-gingerol and 6-shogaol) and Incorporation Assays on Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Design and Synthesis of Some Novel Estrogen Receptor Modulators as Anti-Breast Cancer Agents: In Vitro & In Vivo Screening, Docking Analysis
Anti-Cancer Agents in Medicinal Chemistry Evaluation of Pregabalin Therapy in Peripheral Neuropathy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) A Highly Sensitive Fluorimetric Method for Determination of Cinacalcet Hydrochloride in Tablets and Plasma via Derivatization with 7-Chloro-4- nitrobenzoxadiazole
Current Analytical Chemistry Recent Patents on Anti-Cancer Potential of Helenalin
Recent Patents on Anti-Cancer Drug Discovery Toxicity and Relative Biological Effectiveness of Alpha Emitting Radioimmunoconjugates
Current Radiopharmaceuticals Syntheses and In-Vitro Evaluation of Novel Adamantane Based γ-Secretase Inhibitors
Current Medicinal Chemistry Formation Mechanism of Insulin Fibrils and Structural Aspects of the Insulin Fibrillation Process
Current Protein & Peptide Science Polymeric Nanotubes and Nanorods for Biomedical Applications
Current Nanoscience Mechanisms of Microcystin-induced Cytotoxicity and Apoptosis
Mini-Reviews in Medicinal Chemistry AFM-Based Single Molecule Techniques: Unraveling the Amyloid Pathogenic Species
Current Pharmaceutical Design Modulation of Cytokine Network in the Comorbidity of Schizophrenia and Tuberculosis
Current Topics in Medicinal Chemistry Natural Alkaloids and Diabetes Mellitus: A Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Introduction to the Chirality of Resorcinarenes
Mini-Reviews in Organic Chemistry Design, Synthesis and Biological Evaluation of Novel Tetrahydroquinoline Based Propanehydrazides as Antitubercular Agents
Letters in Drug Design & Discovery